Stock detail

FAES

FAESTOCKS | ES | BME | Healthcare | Drug Manufacturers - Specialty & Generic

Profile snapshotEUR 4.9Market cap EUR 1.5B

No local candle data found.

Recent detected patterns / setups

Latest 10 Market Radar results for this symbol and selected direction.

PatternTFScan runQuality

BullishICT Inverse FVG Setup15M07 Nov 26, 09:1480

BearishMA 21/55 Crossover15M07 Nov 26, 09:1483

BearishSupport/Resistance Flip Setup15M07 Nov 26, 09:1485

BullishICT FVG Setup15M07 Nov 26, 09:1488

BullishICT Breaker Block Setup4H06 Nov 26, 17:1661

BullishSupport/Resistance Flip Setup4H06 Nov 26, 17:1676

BullishOliver Kell Momentum Setup4H06 Nov 26, 17:1679

BullishMA 21/55 Crossover4H06 Nov 26, 17:1680

BullishICT FVG Setup4H06 Nov 26, 17:1681

BullishICT FVG Reaction Setup4H + 15M06 Nov 26, 17:1682

About FAES

FAES (FAE) is listed on BME. Sector: Healthcare. Industry: Drug Manufacturers - Specialty & Generic.

Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants services, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securities and real estate, patents, trademarks and registered brands and equity interests. The company also provides animal nutrition and health products. It offers products for various therapeutic areas. Faes Farma, S.A. was incorporated in 1933 and is headquartered in Leioa, Spain.

Annual

Annual fundamentals

2025 vs previous annual period

Total revenueEUR 610.5M+23.7%

Net incomeEUR 79.6M-28.5%

Net profit margin13.0%-9.5 pp

EPS0.25-28.7%

Total debtEUR 425.5M+21304.3%

Cash and cash equivalentsEUR 117.3M+82.7%

Net debtEUR 308.2M+595.2%

Metric20212022202320242025

Total revenue----EUR 438.8M--EUR 451.2M+2.8%EUR 493.6M+9.4%EUR 610.5M+23.7%

Net income----EUR 89.5M--EUR 91.9M+2.7%EUR 111.4M+21.2%EUR 79.6M-28.5%

Net profit margin----20.4%--20.4%-0.1%22.6%+10.7%13.0%-42.2%

EPS----0.29--0.3+1.0%0.36+20.3%0.25-28.7%

Free cash flow----EUR 26.1M--EUR -1.2M-104.7%EUR 75.9M+6314.5%EUR 54.8M-27.7%

Total debt----EUR 32.7M--EUR 24.4M-25.4%EUR 2M-91.8%EUR 425.5M+21304.3%

Cash and cash equivalents----EUR 66.4M--EUR 34.6M-47.8%EUR 64.2M+85.4%EUR 117.3M+82.7%

Net debt----EUR -33.7M--EUR -10.3M+69.5%EUR -62.2M-505.9%EUR 308.2M+595.2%

Quarterly

Quarterly fundamentals

Q2 2026 vs same quarter previous year

Total revenue----

Net income----

Net profit margin----

EPS----

Total debtEUR 389.3M-8.5%

Cash and cash equivalentsEUR 123.7M+5.4%

Net debtEUR 265.6M-13.8%

MetricQ4 2024Q2 2025Q4 2025Q2 2026

Total revenueEUR 232.5M------EUR 314.3M+35.2%----

Net incomeEUR 53M------EUR 27.3M-48.5%----

Net profit margin22.8%------8.7%-61.9%----

EPS0.17------0.09-47.1%----

Free cash flow----------------

Total debtEUR 22.9M--EUR 95.7M--EUR 425.5M+1758.5%EUR 389.3M+307.0%

Cash and cash equivalentsEUR 64.2M--EUR 103.4M--EUR 117.3M+82.7%EUR 123.7M+19.7%

Net debtEUR -41.3M--EUR -7.7M--EUR 308.2M+845.8%EUR 265.6M+3547.9%

Ownership

Institutional ownership summary

2026 Q4, quarter ended 2026-11-07

PeriodOwnershipInstitutions13F sharesTotal investedPositionsPut/call

2026 Q42026-11-0715.7%--49----------